Arcutis Biotherapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $676.49 million
- Book Value:
- Revenue TTM:
- $3.69 million
- Operating Margin TTM:
- Gross Profit TTM:
- $2.93 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Arcutis Biotherapeutics Inc had its IPO on 2020-01-31 under the ticker symbol ARQT.
The company operates in the Healthcare sector and Biotechnology industry. Arcutis Biotherapeutics Inc has a staff strength of 268 employees.
Shares of Arcutis Biotherapeutics Inc opened at $10.95 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $10.89 - $11.27, and closed at $11.
This is a +0.92% increase from the previous day's closing price.
A total volume of 969,804 shares were traded at the close of the day’s session.
In the last one week, shares of Arcutis Biotherapeutics Inc have increased by +1.85%.
Arcutis Biotherapeutics Inc's Key Ratios
Arcutis Biotherapeutics Inc has a market cap of $676.49 million, indicating a price to book ratio of 3.742 and a price to sales ratio of 1385.7922.
In the last 12-months Arcutis Biotherapeutics Inc’s revenue was $3.69 million with a gross profit of $2.93 million and an EBITDA of $-300692992. The EBITDA ratio measures Arcutis Biotherapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Arcutis Biotherapeutics Inc’s operating margin was -8183.04% while its return on assets stood at -43.97% with a return of equity of -122.8%.
In Q4, Arcutis Biotherapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Arcutis Biotherapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-5.62 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Arcutis Biotherapeutics Inc’s profitability.
Arcutis Biotherapeutics Inc stock is trading at a EV to sales ratio of 1017.8534 and a EV to EBITDA ratio of -2.4478. Its price to sales ratio in the trailing 12-months stood at 1385.7922.
Arcutis Biotherapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $449.27 million
- Total Liabilities
- $37.81 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Arcutis Biotherapeutics Inc ended 2023 with $449.27 million in total assets and $0 in total liabilities. Its intangible assets were valued at $449.27 million while shareholder equity stood at $209.58 million.
Arcutis Biotherapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $37.81 million in other current liabilities, 6000.00 in common stock, $-719764000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $53.64 million and cash and short-term investments were $409.59 million. The company’s total short-term debt was $657,000 while long-term debt stood at $197.77 million.
Arcutis Biotherapeutics Inc’s total current assets stands at $437.41 million while long-term investments were $0 and short-term investments were $355.95 million. Its net receivables were $8.46 million compared to accounts payable of $8.83 million and inventory worth $7.51 million.
In 2023, Arcutis Biotherapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $123000.
Comparatively, Arcutis Biotherapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Arcutis Biotherapeutics Inc stock is currently trading at $11 per share. It touched a 52-week high of $27.4 and a 52-week low of $27.4. Analysts tracking the stock have a 12-month average target price of $54.63.
Its 50-day moving average was $14.45 and 200-day moving average was $18.41 The short ratio stood at 12.53 indicating a short percent outstanding of 0%.
Around 329.8% of the company’s stock are held by insiders while 10940.6% are held by institutions.
Frequently Asked Questions About Arcutis Biotherapeutics Inc
Similar Industry Stocks (Biotechnology)
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.